Vaxcyte, Inc. (PCVX)财务
NASDAQ · Healthcare · Biotechnology · 员工507人 · CEO Grant E. Pickering
- 股价
- $62.03 -0.93%
- 市值
- $97.6亿
- 企业价值
- $97亿
- 最近财报
- Q2 '26 2026-08-05提交
- 下次财报
- 2026-11-03 EPS预期 -$2.11
营收(TTM)$0– 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)–– 对比去年同期营业利润 -$11.7亿
净利润(TTM)-$10.6亿-94.4% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$12亿-124.8% 对比去年同期资本支出 $4060万
稀释EPS(TTM)-$7.64-81.5% 对比去年同期最近4个季度之和
净现金$13.7亿-13.0% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $97.6亿 EV $97亿
- 营收
- $0 过去12个月
- 营收增速
- – FY2026年一致预期
- 净利润率
- – 净利润 / 营收,TTM
- P/E
- -8.1× 预期 -7.5×(FY2026)
- P/S
- 0.0× 股价 / 营收,TTM
- EV / EBITDA
- -9.2× TTM
- 自由现金流
- -$12亿 过去12个月
- 净利润
- -$10.6亿 过去12个月
- 营收预期
- $2500万 FY2026年一致预期
- 盈利
- 2026-11-03 营收预期 $1250万
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-05):营收无,EPS 超预期4.4%营收–,预期$1250万(–);EPS -$1.97,预期-$2.06(+4.4%)。
- 稀释股数一年内增加6.2%Q2 '26稀释股数1.44亿,一年前为1.36亿。
- 净现金 $13.7亿现金 + 短期投资 $14.9亿,含租赁债务 $1.15亿;一年前净现金 $15.8亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $0 | $0 | – |
| 营业利润 | -$3.03亿 | -$2.26亿 | -33.8% |
| 净利润 | -$2.84亿 | -$1.67亿 | -70.7% |
| 稀释EPS | -$1.97 | -$1.22 | -61.5% |
| 经营现金流 | -$5.13亿 | -$1.21亿 | -323.5% |
| 资本支出 | $1940万 | -$1950万 | +199.2% |
| 自由现金流 | -$5.32亿 | -$1.02亿 | -423.8% |
| R&D | $2.68亿 | $1.94亿 | +37.9% |
| 股权激励费用 | $7920万 | $3690万 | +114.5% |
实际 vs 一致预期
2026-08-05| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| EPS(一致预期口径) | -$1.97 | -$2.06 | +4.4% |
来自2026-08-05发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '22 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $70亿 | 0.0% | 100.0% | $210亿 | 0.0% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$11.6亿
- 资本支出
- -$4060万
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $0
- 股权激励费用
- $1.88亿
- 自由现金流
- -$12亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -8.1× | – | – |
| EV / EBITDA | -9.2× | – | – |
| EV / 营收 | 0.0× | – | – |
| 股价 / FCF | -8.1× | – | – |
| 股价 / 净资产 | 3.2× | 3.6× | 2.3× – 4.9× |
| FCF收益率 | -12.3% | -7.5% | -10.7% – -4.8% |
| 投入资本回报率 | -40.6% | -28.9% | -36.9% – -16.9% |
| 净资产收益率 | -37.6% | -26.7% | -35.2% – -14.0% |
分析师
一致目标价 $122.33 (+97.2%)
区间 $120.00 – $125.00 · 评级 Buy
强烈买入0
买入11
持有0
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $2500万 | – | -$8.23 | -46.1% | -7.5× | 6 |
| FY2027 | $8710万 | +248.6% | -$6.50 | +21.0% | -9.5× | 6 |
| FY2028 | $9790万 | +12.4% | -$6.44 | +1.0% | -9.6× | 6 |
| FY2029 | $14.1亿 | +1,339.3% | $0.74 | +111.6% | 83.4× | 3 |
| FY2030 | $22亿 | +56.0% | $5.18 | +596.9% | 12.0× | 2 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Vaxcyte, Inc.在近期10-Q / 10-K文件中标记的全部172项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $1.01亿 | $3140万 | +221.3% | $7090万 | $4850万 | +46.3% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $118万 | $449万 | -73.7% | $1440万 | $3870万 | -62.7% |
| Accrued Liabilities, Current | $2470万 | $3220万 | -23.2% | $3110万 | $2910万 | +6.7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3280万2025-12-31 | $1630万 | +101.4% | $3280万 | $1630万 | +101.4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$755万 | -$189万 | -299.9% | $159万 | -$387万 | +141.0% |
| Additional Paid in Capital, Common Stock | $55.3亿 | $47.7亿 | +15.9% | $48.4亿 | $47亿 | +3.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1540万 | 1330万 | +16.2% | 1450万 | 1160万 | +25.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $4120万 | $3690万 | +11.7% | $1.39亿 | $8480万 | +63.7% |
| Assets | $31.4亿 | $33.1亿 | -5.1% | $30亿 | $35.1亿 | -14.5% |
| Assets, Current | $15.5亿 | $17.2亿 | -9.5% | $16.3亿 | $17.9亿 | -9.0% |
| Assets, Noncurrent | $15.9亿 | $15.9亿 | -0.3% | $13.8亿 | $17.2亿 | -20.2% |
| Capital Expenditures Incurred but Not yet Paid | -$168万 | -$41.8万 | -302.9% | $754万 | $1320万 | -42.8% |
| Cash and Cash Equivalents, at Carrying Value | $1.83亿 | $3.07亿 | -40.3% | $1.74亿 | $3.88亿 | -55.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.85亿 | $3.08亿 | -40.1% | $1.75亿 | $3.89亿 | -54.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$7770万 | -$4010万 | -93.6% | -$2.14亿 | -$936万 | -2,184.1% |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 546万2026-03-31 | 350万 | +56.1% | – | – | – |
| Common Stock, Dividends, Per Share, Declared | – | – | – | $0.00 | $0.00 | – |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 5亿 | 5亿 | 0.0% | 5亿 | 5亿 | 0.0% |
| Common Stock, Shares, Issued | 1.45亿 | 1.3亿 | +11.5% | 1.31亿 | 1.25亿 | +4.9% |
| Common Stock, Shares, Outstanding | 1.45亿 | 1.3亿 | +11.5% | 1.31亿 | 1.25亿 | +4.9% |
| Common Stock, Value, Issued | $14.8万 | $13.3万 | +11.3% | $13.4万 | $12.8万 | +4.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$2.85亿 | -$1.68亿 | -69.5% | -$7.61亿 | -$4.68亿 | -62.7% |
| Debt Securities, Available-for-sale | $23.2亿 | $25.2亿 | -7.7% | $22.7亿 | $27.5亿 | -17.4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $4.27亿 | $410万 | +10,312.2% | $1.2亿 | $1050万 | +1,044.8% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $740万 | – | – | – | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $10.2亿 | $11.7亿 | -12.4% | $8.82亿 | $13.9亿 | -36.5% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $13亿 | $13.5亿 | -3.8% | $13.9亿 | $13.6亿 | +2.0% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $18亿 | $13亿 | +38.5% | $3亿 | $15亿 | -80.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $2730万2025-12-31 | $2930万 | -6.5% | $2730万 | $2930万 | -6.5% |
| Deferred Tax Assets, Gross | $6.89亿2025-12-31 | $4.68亿 | +47.1% | $6.89亿 | $4.68亿 | +47.1% |
| Deferred Tax Assets, in Process Research and Development | $2.21亿2025-12-31 | $1.55亿 | +42.4% | $2.21亿 | $1.55亿 | +42.4% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Net of Valuation Allowance | $4320万2025-12-31 | $2200万 | +96.8% | $4320万 | $2200万 | +96.8% |
| Deferred Tax Assets, Operating Loss Carryforwards | $3.36亿2025-12-31 | $1.96亿 | +71.6% | $3.36亿 | $1.96亿 | +71.6% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $3830万2025-12-31 | $2670万 | +43.3% | $3830万 | $2670万 | +43.3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $2280万2025-12-31 | $1470万 | +55.6% | $2280万 | $1470万 | +55.6% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other | $647万2025-12-31 | $1460万 | -55.8% | $647万 | $1460万 | -55.8% |
| Deferred Tax Assets, Valuation Allowance | $6.45亿2025-12-31 | $4.46亿 | +44.7% | $6.45亿 | $4.46亿 | +44.7% |
| Deferred Tax Liabilities, Gross | $4320万2025-12-31 | $2200万 | +96.8% | $4320万 | $2200万 | +96.8% |
| Deferred Tax Liabilities, Leasing Arrangements | $3470万2025-12-31 | $2150万 | +61.1% | $3470万 | $2150万 | +61.1% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $130万2025-12-31 | $45.6万 | +184.0% | $130万 | $45.6万 | +184.0% |
| Depreciation, Depletion and Amortization | $300万 | $288万 | +4.3% | $1640万 | $700万 | +134.1% |
| Depreciation, Depletion and Amortization, Nonproduction | – | – | – | $1640万 | $700万 | +134.3% |
| Earnings Per Share, Basic | -$1.97 | -$1.22 | -61.5% | -$5.63 | -$3.80 | -48.2% |
| Earnings Per Share, Diluted | -$1.97 | -$1.22 | -61.5% | -$5.63 | -$3.80 | -48.2% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $140万 | $80万 | +74.6% | $244万 | $42.6万 | +472.5% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$1.61亿 | -$9740万 | -65.0% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21.0% | 21.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $1.4亿 | $1.09亿 | +28.6% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -18.2% | -23.4% | +22.2% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | – | – | – | $327万 | $211万 | +55.0% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | – | – | – | -0.4% | -0.5% | +20.0% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $309万 | -$1850万 | +116.7% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | – | – | – | -0.4% | 4.0% | -110.0% |
| Effective Income Tax Rate Reconciliation, Percent | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | – | – | – | -$2.9万 | $6.5万 | -144.6% |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | – | – | – | $871万 | $1130万 | -22.9% |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | – | – | – | -1.1% | -2.4% | +54.2% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02